Novigenix Welcomes Dr. Miro Venturi to its Board of Directors

Miro Venturi brings with him his deep proficiency in precision medicine, mainly as former Senior VP at Roche and Foundation Medicine.

FREMONT, CA: Novigenix SA, a top Swiss biotech that produces and commercializes Immuno-Transcriptomic precision oncology solutions, has elected Dr. Miro Venturi to its Board of Directors. Dr. Venturi is currently the Group CEO of Sintetica SA, a Swiss-based global pharmaceutical firm, and he brings deep proficiency in precision medicine, particularly as former Senior VP at Roche and Foundation Medicine.

Dr. Brian Hashemi, Executive Chairman of Novigenix, said, “We are delighted to welcome Dr. Venturi to the Board of Novigenix as we expand our biopharma partnerships, and application of ImmunoTranscriptomic precision oncology solutions in drug development and clinical utility programs. 

Miro’s tremendous expertise in development of novel biomarkers brings a valuable perspective in creating value along the patient journey, and we look forward to his contribution as we scale up delivery of unique biopharma solutions to improve patient outcomes.”

"Novigenix has already demonstrated the value of its ImmunoTranscriptomics platform for early cancer detection. The team is now making great progress towards therapy response prediction and monitoring based on data-driven immune insights. I am very much looking forward to supporting the team in delivering differentiated solutions that can significantly improve patient outcomes and clinical utility of therapeutic modalities,” said Dr. Miro Venturi, former Senior VP, Global Head Diagnostics Biomarkers & Personalized Healthcare at Roche, and Senior VP, Head Biopharma at Foundation Medicine.